LB-102
Schizophrenia
Key Facts
About LB Pharmaceuticals
LB Pharmaceuticals (NASDAQ: LBRX) is a clinical-stage biotech company founded in 2019 with a mission to develop novel therapies for severe neuropsychiatric disorders. Its core strategy centers on the rational optimization of amisulpride to create LB-102, a potential first-in-class benzamide antipsychotic for the U.S. market, aiming to reduce development risk while pursuing meaningful clinical differentiation. The company has advanced LB-102 into Phase 2 clinical trials, assembled a leadership team with deep neuropsychiatric expertise, and is backed by a board with significant biotech and venture capital experience.
View full company profileAbout LB Pharmaceuticals
LB Pharmaceuticals (NASDAQ: LBRX) is a clinical-stage biotech company founded in 2019 with a mission to develop novel therapies for severe neuropsychiatric disorders. Its core strategy centers on the rational optimization of amisulpride to create LB-102, a potential first-in-class benzamide antipsychotic for the U.S. market, aiming to reduce development risk while pursuing meaningful clinical differentiation. The company has advanced LB-102 into Phase 2 clinical trials, assembled a leadership team with deep neuropsychiatric expertise, and is backed by a board with significant biotech and venture capital experience.
View full company profileAbout LB Pharmaceuticals
LB Pharmaceuticals (NASDAQ: LBRX) is a clinical-stage biotech company founded in 2019 with a mission to develop novel therapies for severe neuropsychiatric disorders. Its core strategy centers on the rational optimization of amisulpride to create LB-102, a potential first-in-class benzamide antipsychotic for the U.S. market, aiming to reduce development risk while pursuing meaningful clinical differentiation. The company has advanced LB-102 into Phase 2 clinical trials, assembled a leadership team with deep neuropsychiatric expertise, and is backed by a board with significant biotech and venture capital experience.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |